Factors Affecting Steady-state Plasma Concentrations of Enantiomeric Mirtazapine and its Desmethylated Metabolites in Japanese Psychiatric Patients

被引:5
作者
Hayashi, Y. [1 ]
Watanabe, T. [1 ]
Aoki, A. [1 ]
Ishiguro, S. [1 ]
Ueda, M. [1 ]
Akiyama, K. [2 ]
Kato, K. [3 ]
Inoue, Y. [1 ]
Tsuchimine, S. [4 ]
Yasui-Furukori, N. [4 ]
Shimoda, K. [1 ]
机构
[1] Dokkyo Med Univ, Sch Med, Dept Psychiat, Shimotsuga, Tochigi 3210293, Japan
[2] Dokkyo Med Univ, Sch Med, Dept Biol Psychiat & Neurosci, Shimotsuga, Tochigi 3210293, Japan
[3] Sakura La Mental Clin, Utsunomiya, Tochigi, Japan
[4] Hirosaki Univ, Grad Sch Med, Dept Neuropsychiat, Hirosaki, Aomori, Japan
关键词
mirtazapine; enantiomer; CYP2D6*10; pharmacokinetics; pharmacogenetics; CYP2D6; GENOTYPE; IN-VITRO; ANTIDEPRESSANT MIRTAZAPINE; PHARMACOKINETICS; HYDROXYLATION; MIANSERIN; 8-HYDROXYMIRTAZAPINE; TRANSMISSION; POPULATION; ORG-3770;
D O I
10.1055/s-0035-1565069
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: This study evaluated the effects of the CYP2D6 * 10 genotype on steady-state plasma concentrations of enantiomeric mirtazapine (MIR) and N-desmethylmirtazapine (DMIR) in Japanese patients. Methods: Subjects were 77 Japanese patients treated with racemic MIR. Steady-state plasma concentrations of MIR and DMIR enantiomers were measured using stereoselective liquid chromatography. Polymerase chain reaction was used to determine the CYP2D6 genotypes. Results: After correcting for dose and body weight, smokers (n = 15) had significantly lower S-(+)-MIR than nonsmokers (n = 55) (15.1 +/- 17.8 vs. 23.9 +/- 17.8 ng/mL/mg/kg, Kruskal-Wallis test, p = 0.034). One-way analysis of variance revealed that CYP2D6 * 10 homozygotes had significantly higher corrected plasma concentrations of S-(+)-MIR than the no-variant allele group (p = 0.034). Multiple regression analysis revealed a significant positive correlation between the number of CYP2D6 * 10 alleles and corrected plasma concentrations of S-(+)-MIR. These results yielded the following final model: corrected plasma concentration of S-(+)-MIR = 15.9 + 7.30 x (number of CYP2D6 * 10 alleles) (R = 0.279, p = 0.023, coefficient of determination (R-2) = 0.078). Conclusion: Homozygous CYP2D6 * 10 alleles and smoking have a significant impact on the metabolism of S-(+)-MIR in Japanese patients.
引用
收藏
页码:279 / 285
页数:7
相关论文
共 27 条
[1]   Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers [J].
Borobia, Alberto M. ;
Novalbos, Jesus ;
Guerra-Lopez, Pedro ;
Lopez-Rodriguez, Rosario ;
Tabares, Beatriz ;
Rodriguez, Vanesa ;
Abad-Santos, Francisco ;
Carcas, Antonio J. .
PHARMACOLOGICAL RESEARCH, 2009, 59 (06) :393-398
[2]   Pharmacokinetics of mirtazapine:: Enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects [J].
Brockmoeller, J. ;
Meineke, I. ;
Kirchheiner, J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) :699-707
[3]   DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION [J].
BROLY, F ;
GAEDIGK, A ;
HEIM, M ;
EICHELBAUM, M ;
MORIKE, K ;
MEYER, UA .
DNA AND CELL BIOLOGY, 1991, 10 (08) :545-558
[4]   In vitro and in vivo studies on the disposition of mirtazapine in humans [J].
Dahl, ML ;
Voortman, G ;
Alm, C ;
Elwin, CE ;
Delbressine, L ;
Vos, R ;
Bogaards, JJP ;
Bertilsson, L .
CLINICAL DRUG INVESTIGATION, 1997, 13 (01) :37-46
[5]   ANALYSIS OF THE CYP2D6 GENE IN RELATION TO DEBRISOQUIN AND DESIPRAMINE HYDROXYLATION IN A SWEDISH POPULATION [J].
DAHL, ML ;
JOHANSSON, I ;
PALMERTZ, MP ;
INGELMANSUNDBERG, M ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (01) :12-17
[6]  
deBoer T, 1996, J PHARMACOL EXP THER, V277, P852
[7]   NEUROCHEMICAL AND AUTONOMIC PHARMACOLOGICAL PROFILES OF THE 6-AZA-ANALOGUE OF MIANSERIN, ORG-3770 AND ITS ENANTIOMERS [J].
DEBOER, T ;
MAURA, G ;
RAITERI, M ;
DEVOS, CJ ;
WIERINGA, J ;
PINDER, RM .
NEUROPHARMACOLOGY, 1988, 27 (04) :399-408
[8]   THE ALPHA(2)-ADRENOCEPTOR ANTAGONIST ORG-3770 ENHANCES SEROTONIN TRANSMISSION IN-VIVO [J].
DEBOER, T ;
NEFKENS, F ;
VANHELVOIRT, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 253 (1-2) :R5-R6
[9]   The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission [J].
deBoer, T .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 :19-23
[10]   Pharmacokinetics and biotransformation of mirtazapine in human volunteers [J].
Delbressine, LPC ;
Moonen, MEG ;
Kaspersen, FM ;
Wagenaars, GN ;
Jacobs, PL ;
Timmer, CJ ;
Paanakker, JE ;
van Hal, HJM ;
Voortman, G .
CLINICAL DRUG INVESTIGATION, 1998, 15 (01) :45-55